Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQC2731 Phase I in Healthy Subjects and Patients with Severe Asthma
NCT04923607Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2021
- Primary completion
- Aug 2023
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bosakitug in severe asthma (8 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Number of participants with abnormal clinical symptoms at Day 253, Number of participants with abnormal physical examination at Day 253 and 2 more. Status: unknown.
02
Drugs
bosakitug
03
Conditions
severe asthma
Beyond the preview
Go deeper on NCT04923607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04923607.